Abstract：
UNASSIGNED: Interleukin (IL)-4 and IL-13 are considered key drivers of type 2 inflammatory diseases. Dupilumab is a fully human monoclonal antibody that blocks the shared receptor component for IL-4 and IL-13, thus inhibiting signaling of both cytokines.
UNASSIGNED: We report a case of a patient with uncontrolled severe asthma and other T2 inflammatory diseases (atopic dermatitis, chronic rhinosinusitis with nasal polyposis and eosinophilic esophagitis) treated with dupilumab.
UNASSIGNED: After one year of treatment, dupilumab improved asthma control together with lung function parameters and airway inflammation. Additionally, a positive impact on quality of life (QoL), evaluated by validated questionnaires, across all the diseases was observed.
UNASSIGNED: In this case report, a positive and objectively measurable of global improvement on QoL across all four T2 comorbidities was observed after treatment with dupilumab, demonstrating the important role of IL-4 and IL-13 and the existence of a unifying pathological mechanism in T2 diseases.
UNASSIGNED: We report a case of a patient with uncontrolled severe asthma and other T2 inflammatory diseases (atopic dermatitis, chronic rhinosinusitis with nasal polyposis and eosinophilic esophagitis) treated with dupilumab.
UNASSIGNED: After one year of treatment, dupilumab improved asthma control together with lung function parameters and airway inflammation. Additionally, a positive impact on quality of life (QoL), evaluated by validated questionnaires, across all the diseases was observed.
UNASSIGNED: In this case report, a positive and objectively measurable of global improvement on QoL across all four T2 comorbidities was observed after treatment with dupilumab, demonstrating the important role of IL-4 and IL-13 and the existence of a unifying pathological mechanism in T2 diseases.
摘要：
■白细胞介素（IL）-4和IL-13被认为是2型炎症性疾病的关键驱动因素。Dupilumab是一种全人单克隆抗体，可阻断IL-4和IL-13的共有受体成分，从而抑制两种细胞因子的信号传导。案例研究：我们报告了一例未控制的严重哮喘和其他T2炎症性疾病（特应性皮炎，慢性鼻窦炎伴鼻息肉病和嗜酸性粒细胞性食管炎）用dupilumab治疗。
■治疗一年后，dupilumab改善了哮喘控制以及肺功能参数和气道炎症.此外,对生活质量(QoL)的积极影响，通过经过验证的问卷进行评估，所有的疾病都被观察到了。
■在此案例报告中，在使用dupilumab治疗后，观察到所有四种T2合并症的QoL总体改善，证明了IL-4和IL-13在T2疾病中的重要作用以及统一的病理机制的存在。
■治疗一年后，dupilumab改善了哮喘控制以及肺功能参数和气道炎症.此外,对生活质量(QoL)的积极影响，通过经过验证的问卷进行评估，所有的疾病都被观察到了。
■在此案例报告中，在使用dupilumab治疗后，观察到所有四种T2合并症的QoL总体改善，证明了IL-4和IL-13在T2疾病中的重要作用以及统一的病理机制的存在。
